Enzyre, a Nijmegen, The Netherlands-based developer of diagnostic technology, received a €1.4m Corona Bridge Loan.
Novalis Biotechnology Incubation, through its seed fund, participated as co-financer in the loan, which was granted by the Dutch government.
A spin-out from Radboud University Medical Center in The Netherlands, led by Dirk Pollet, CEO, Enzyre was established to develop an innovative near patient test (NPT) device named Enzypad to measure biomarkers in body fluids. The first application of Enzypad will monitor hemophilia by providing a real-time picture of a patient’s blood coagulation status. The result of each test made by a patient is sent automatically to the treating physicians through an app on a mobile phone.
The platform technology requires just a small volume of blood and is able to measure up to twelve (12) biomarkers simultaneously without any laboratory infrastructure; at home, on the road or in a critical care setting. In December 2019, the company signed a collaboration with Takeda for the development of Enzypad in congenital bleeding disorders, validating this innovative approach.
FinSMEs
27/07/2020